Mulmit

BIOMERICA INCBIOMERICA INC

BMRA Nasdaq

Annual financials

PeriodRevenueOperating incomeNet incomeEPS
2026-05-314,453,000-5,320,000-3,775,000-1.3
2025-05-315,311,000-5,137,000-4,973,000-2.16
2024-05-315,415,000-6,367,000-5,978,000-2.84
2023-05-315,339,000-7,223,000-7,140,000-0.5
2022-05-3118,871,000-4,534,000-4,531,000-0.36

Insider filings (Forms 3/4/5)

DateOwnerTitleShares
2026-08-26MOATAZEDI DAVID10,000
2026-08-26Chin Eric6,250
2026-08-26BARBIERI ALLENExecutive Vice Chairman20,000
2026-08-26Irani Zackary S.Chief Executive Officer31,250
2026-08-20Gary M. Huff31,250
2025-12-12Chin Eric22,500
2025-12-12Lu GaryChief Financial Officer40,000
2025-12-12Irani Zackary S.Chief Executive Officer52,500
2025-12-12BARBIERI ALLENExecutive Vice-Chairman30,000
2025-12-12Gary M. Huff20,000
2025-12-12MOATAZEDI DAVID20,000
2024-12-13MOATAZEDI DAVID85,000

8-K events

FiledItems
2026-08-26Entry into a material agreement · Unregistered sales of equity securities · Financial statements and exhibits
2026-06-04Entry into a material agreement · Creation of a direct financial obligation · Financial statements and exhibits
2025-12-16Submission of matters to a vote
2025-10-08Officer or director change · Regulation FD disclosure · Financial statements and exhibits
2025-06-06Officer or director change · Regulation FD disclosure · Financial statements and exhibits
2025-04-16Material modification to rights of security holders · Amendments to charter or bylaws · Regulation FD disclosure · Financial statements and exhibits
2024-12-17Submission of matters to a vote
2024-11-06Delisting or listing-standard notice
데이터를 불러오는 중입니다…Loading…

가격 차트Price chart

차트를 불러오는 중입니다…Loading chart…

In Vitro & In Vivo Diagnostic Substances — 같은 업종, 그리고 규모가 비슷한 기업In Vitro & In Vivo Diagnostic Substances — and other companies of a similar size

SEC가 같은 업종(In Vitro & In Vivo Diagnostic Substances)으로 분류한 기업이 먼저 오고, 그다음은 제출된 매출로 가까운 순입니다 — 가장 최근 연간 값이며, 연간 값이 없으면 최근 네 분기 합입니다. Companies the SEC assigns to the same industry (In Vitro & In Vivo Diagnostic Substances) come first, then the nearest by revenue as filed — the latest annual figure, or the last four quarters where no annual one is filed. 순서일 뿐 값이 싸거나 비싸다는 뜻이 아닙니다.Order only — it does not say a company is cheap or expensive.